KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Non-Current Liabilities: 2017-2024

Historic Other Non-Current Liabilities for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $267.0 million.

  • Moderna's Other Non-Current Liabilities rose 1.81% to $281.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.0 million, marking a year-over-year increase of 1.81%. This contributed to the annual value of $267.0 million for FY2024, which is 4.30% up from last year.
  • Latest data reveals that Moderna reported Other Non-Current Liabilities of $267.0 million as of FY2024, which was up 4.30% from $256.0 million recorded in FY2023.
  • Over the past 5 years, Moderna's Other Non-Current Liabilities peaked at $267.0 million during FY2024, and registered a low of $3.0 million during FY2020.
  • In the last 3 years, Moderna's Other Non-Current Liabilities had a median value of $256.0 million in 2023 and averaged $219.3 million.
  • Data for Moderna's Other Non-Current Liabilities shows a peak YoY soared of 2,433.33% (in 2021) over the last 5 years.
  • Over the past 5 years, Moderna's Other Non-Current Liabilities (Yearly) stood at $3.0 million in 2020, then soared by 2,433.33% to $76.0 million in 2021, then surged by 77.63% to $135.0 million in 2022, then surged by 89.63% to $256.0 million in 2023, then climbed by 4.30% to $267.0 million in 2024.